The University of Sydney Drug Discovery Initiative unites researchers, clinicians and industry to develop drugs that improve human health.
This project grant supports the development of metal chelators for the selective delivery of medically-relevant metals to tumours to improve radiation therapy results. This work will aid in the generation of gadolinium nanoparticles to treat and monitor brain cancer.
The grant lead by A/Prof Louis Rendina from the School of Chemistry brings together 12 senior, mid, and early-career researchers from across The University of Sydney Schools, Centres and Institutes, which includes the Bill Walsh Lab and The Brain Cancer Group researchers A/Prof Viive Howell and Dr Kelly McKelvey.
The USyd DDI website is www.sydney.edu.au/research/centres/drug-discovery-initiative.html